Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE)
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q1Scopus Q1
- 저널
- BRITISH JOURNAL OF HAEMATOLOGY189(2) · pp.303 · 2020
- 피인용
- Web of Science 21Scopus 23
- FWCI (Scopus)
- 0
- JCR IF
- JCR 2019 5.518
- ISSN
- 0007-1048
저자
- Do, Young Rok제1저자Dongsan Medical Center, Keimyung University, Daegu, South Korea
- Kwak, Jae-YongChonbuk National University Medical School & Hospital, Jeonju, South Korea
- Kim, Jeong A.St. Vincent Hospital, The Catholic University of Korea, Suwon, South Korea
- Kim, Hyeoung JoonChonnam National University, Hwasun Hospital, Hwasun, South Korea
- 정주섭Pusan National University Hospital, Busan, South Korea
- 신호진Pusan National University Hospital, Busan, South Korea
- Kim, Sung-HyunDong-A University Medical Center, Busan, South Korea
- Bunworasate, UdomsakKing Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, Thailand
- Choi, Chul WonKorea University, Guro Hospital, Seoul, South Korea
- Zang, Dae YoungHallym University Sacred Heart Hospital, Anyang, South Korea
- Oh, Suk JoongKangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea
- Jootar, SaengsureeFaculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
- Reksodiputro, Ary HarryantoRumah Sakit Dr, Cipto Mangunkusumo Hospital, Jakarta, Indonesia
- Lee, Won SikInje University Busan Paik Hospital, Busan, South Korea
- Mun, Yeung-ChulEwha Womans University College of Medicine, Seoul, South Korea
- Kong, Jee HyunWonju Severance Christian Hospital, Wonju, South Korea
- Caguioa, Priscilla B.St. Luke’s Medical Center, Quezon, Philippines
- Kim, HawkGachon University Gil Medical Center, Gachon University College of Medicine, Incheon, South Korea
- Park, JinnyGachon University Gil Medical Center, Gachon University College of Medicine, Incheon, South Korea
- Kim, Dong-Wook교신저자Seoul St. Mary's Hematology Hospital, Leukemia Research Institute, The Catholic University of Korea, Seoul, South Korea
초록
In the phase 3 study RERISE, patients with newly diagnosed chronic myeloid leukaemia in chronic phase demonstrated significantly faster and higher rates of major molecular response (MMR) with twice-daily radotinib 300 mg (n = 79) or 400 mg (n = 81) than with once-daily imatinib 400 mg (n = 81) after 12 months. With >= 48 months' follow-up, MMR was higher with radotinib 300 mg (86%) or 400 mg (83%) than with imatinib (75%). Among patients with BCR-ABL1 <= 10% at three months, MMR and molecular response 4 center dot 5 (MR4 center dot 5) were achieved within 48 months by more radotinib-treated patients (300 mg: 84% and 52%, respectively; 400 mg: 74% and 44%, respectively) than imatinib-treated patients (71% and 44%, respectively). Estimated overall and progression-free survival rates at 48 months were not significantly different between imatinib (94% and 94%, respectively) and radotinib 300 mg (99% and 97%, respectively) or 400 mg (95% and 93%, respectively). The treatment failure rate was significantly higher with imatinib (19%) than with radotinib 300 mg (6%; P = 0 center dot 0197) or 400 mg (5%; P = 0 center dot 0072). Safety profiles were consistent with previous reports; most adverse events occurred within 12 months. Radotinib continues to demonstrate robust, deep molecular responses, suggesting that treatment-free remission may be attainable.
키워드
chronic myeloid leukaemiaimatinibnewly diagnosedlong-term dataradotinibDASATINIBTRIALDISCONTINUATIONINHIBITORNILOTINIBEFFICACYTHERAPYSAFETY
식별자
- Scopus EID
- 2-s2.0-85078900629
- WoS UID
- 000510537100001



로그인
연구물 목록으로